Agouron

Agouron Pharmaceuticals. CytoGenix. Ligand Pharmaceuticals. SangStat... 

Nelfinavir, Viracept, AG1343 Agouron HIV protease Transition state analog... 

Agouron (now Pfizer) disclosed in a series of patents the discovery of potent CDK inhibitors based on the 5-benzoyl-2,4 diaminothiazole template [130, 131]. Compounds 66 and 67 were both potent CDK2 inhibitors (66 Ki < 0.005 xM 67 Ki = 0.10 xM), but these compounds varied in their activity... 

Pfizer (New York, NY, www.pfizer.com), in collaboration with its wholly-owned subsidiary Agouron Pharmaceuticals, is developing Axitinib (AG-... 

The Agouron Institute and the Peptide Biology Laboratory, The Salk Institute, La Jolla,... 

Viracept (nelfinavir, AG-1343) of Agouron (La Jolla/CA, USA) in collaboration with Japan Tobacco (Tokyo, Japan) began only in July 1995 with phase II investigations. Dosages in phase II are set between 770 and 1030 mg daily. The viral count decreased between 15- and 75-fold in comparison with the base case. 

Another consideration which affects the value of an asset is the currency that is used to pay for it cash, equity or goodwill. Equity in place of cash can either be a compelling offer or quite the opposite. On many occasions when evaluating the value of a potential acquisition target the value of a cash bid compared to the headline value that other companies were prepared to offer in the form of shares in their own company made poor comparison. The acquisition of Agouron by Warner-Lambert in 1999 was one of several deals at the time which were funded by an offer of stock of the acquiring company. 

D Viracept (Roche) GB Viracept (Roche) USA Viracept (Agouron)... 

Phase 2 Pfizer, Agouron AG-13736 Cancer VEGF, PDGF... 

Agouron began with consideration of the structure of the complex between the E. coll enzyme and 5-deazatetrahydrofolate (77). An active and soluble fragment of a multifunctional human protein that contained the GARFT activity was provided by recombinant approaches (78), and its structure was also solved (79) in complex with novel inhibitors. Comparison of the two structures subsequently validated the use of the bacterial enzyme as a model for the human GARFT. The design of novel inhibitors also relied on previous studies of the structure-activity relationships (SAR) for substitutents around the core... 

---